| Company Name: |
Nanjing Chemlin Chemical Co., Ltd
|
| Tel: |
025-83697070 13770331960 |
| Email: |
info@chemlin.com.cn |
| Products Intro: |
Product Name:NEO2734; Neo 2734 CAS:2081072-29-7
|
NEO2734 manufacturers
- NEO2734
-
- $116.00 / 1mg
-
2026-03-13
- CAS:2081072-29-7
- Min. Order:
- Purity: 98.72%
- Supply Ability: 10g
|
| | NEO2734 Basic information |
| Product Name: | NEO2734 | | Synonyms: | NEO2734;EP31670;NEO2734 (EP31670);PER-403,SPOP,NEO-2734,CBP,NEO 2734,MYC,HAT,NEO2734,Epigenetic Reader Domain,TC-797,Histone Acetyltransferase,p300,HATs,inhibit,Inhibitor,EP-31670,EP 31670;2(1H)-Pyridinone, 1,3-dimethyl-5-[2-(tetrahydro-2H-pyran-4-yl)-1-[2-(trifluoromethoxy)ethyl]-1H-benzimidazol-6-yl]-;NEO2734, 10 mM in DMSO;1,3-Dimethyl-5-(2-(tetrahydro-2H-pyran-4-yl)-1-(2-(trifluoromethoxy)ethyl)-1H-benzimidazol-6-yl)-2(1H)-pyridinone;NEO2734 ,S9648 | | CAS: | 2081072-29-7 | | MF: | C22H24F3N3O3 | | MW: | 435.44 | | EINECS: | | | Product Categories: | | | Mol File: | 2081072-29-7.mol |  |
| | NEO2734 Chemical Properties |
| Boiling point | 598.0±50.0 °C(Predicted) | | density | 1.35±0.1 g/cm3(Predicted) | | solubility | DMSO: Sparingly Soluble: 1-10 mg/ml Ethanol: Sparingly Soluble: 1-10 mg/ml | | form | Solid | | pka | 4.83±0.10(Predicted) | | color | White to off-white |
| | NEO2734 Usage And Synthesis |
| Uses | NEO2734 (EP31670) is an orally active dual p300/CBP and BET bromodomain selective inhibitor, with IC50 values of <30 nM for both p300/CBP and BET bromodomains[1]. NEO2734 is active in SPOP mutant and wild-type prostate cancer[2]. | | in vivo | NEO2734 (5, 8, 10 mg/kg, orally) inhibits growth and prolongs survival in pre-clinical xenograft models[1].
| Animal Model: | Mice (PER-403 and 14169 models)[1]. | | Dosage: | 5, 8, 10 mg/kg | | Administration: | Orally, once daily for 28 days. | | Result: | Two of the three mice treated with NEO2734 were alive by day 100.
Provided markedly improved survival compared with EP, i-BET-762, and even iBET-762+EP by day 100 following initiation of treatment.
|
| | IC 50 | CBP/p300 | | References | [1] Chevaun D Morrison-Smit, et al. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734. Mol Cancer Ther. 2020 Jul;19(7):1406-1414. DOI:10.1158/1535-7163.MCT-20-0087 [2] Yuqian Yan, et al. The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer. EMBO Mol Med. 2019 Nov 7;11(11):e10659. DOI:10.15252/emmm.201910659 [3] De Souza, F.I., Zumiotti, A.V., and Da Silva, C.F. Neuregulins 1-α and 1-β on the regeneration the peripheral nerves[J]. Acta Ortop Bras. |
| | NEO2734 Preparation Products And Raw materials |
|